These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20684745)

  • 21. Developing treatment guidelines for Alzheimer's disease and other dementias.
    Rabins PV
    J Clin Psychiatry; 1996; 57 Suppl 14():37-8. PubMed ID: 9024335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atypical antipsychotics for neuropsychiatric symptoms of dementia: malignant or maligned?
    Herrmann N; Lanctôt KL
    Drug Saf; 2006; 29(10):833-43. PubMed ID: 16970508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical inquiries. Which drugs are best when aggressive Alzheimer's patients need medication?
    Mohundro BL; Pope K; Shaw V; Hitchcock K
    J Fam Pract; 2010 Oct; 59(10):595-604. PubMed ID: 20922181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical perspectives on atypical antipsychotics for treatment of agitation.
    Caine ED
    J Clin Psychiatry; 2006; 67 Suppl 10():22-31. PubMed ID: 16965192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
    Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Greenspan A
    Int J Geriatr Psychiatry; 2005 Dec; 20(12):1153-7. PubMed ID: 16315159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Agitation and aggression in people with Alzheimer's disease.
    Ballard C; Corbett A
    Curr Opin Psychiatry; 2013 May; 26(3):252-9. PubMed ID: 23528917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacotherapy for behavioral and psychological symptoms of dementia in the elderly.
    Beier MT
    Am J Health Syst Pharm; 2007 Jan; 64(2 Suppl 1):S9-17; quiz S24-5. PubMed ID: 17215476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of atypical antipsychotics for behavioral symptoms of dementia among patients residing in long-term care.
    Sturm AS; Trinkley KE; Porter K; Nahata MC
    Int J Clin Pharm; 2018 Feb; 40(1):135-142. PubMed ID: 29189977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Agitation and psychosis in dementia.
    Ballard C
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):913-7. PubMed ID: 17974863
    [No Abstract]   [Full Text] [Related]  

  • 31. Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia.
    De Deyn PP; Wirshing WC
    J Clin Psychiatry; 2001; 62 Suppl 21():19-22. PubMed ID: 11584983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Atypical antipsychotics and CATIE-AD. Is this a turning point?].
    Bustin J
    Vertex; 2009; 20(84):136-43. PubMed ID: 19543565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer's disease.
    Creese B; Da Silva MV; Johar I; Ballard C
    Expert Rev Neurother; 2018 Jun; 18(6):461-467. PubMed ID: 29764230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
    Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of safety warnings on antipsychotic prescriptions in dementia: nothing has changed but the years and the substances.
    Schulze J; van den Bussche H; Glaeske G; Kaduszkiewicz H; Wiese B; Hoffmann F
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1034-42. PubMed ID: 23498307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of agitation and aggression associated with Alzheimer disease.
    Ballard CG; Gauthier S; Cummings JL; Brodaty H; Grossberg GT; Robert P; Lyketsos CG
    Nat Rev Neurol; 2009 May; 5(5):245-55. PubMed ID: 19488082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Recognition and treatment of behavioral and psychological symptoms of dementias: lessons from the CATIE-AD study].
    Kálmán J; Kálmán S; Pákáski M
    Neuropsychopharmacol Hung; 2008 Oct; 10(4):233-49. PubMed ID: 19213202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in pharmacological treatment of psychosis in late life.
    Chan WC; Lam LC; Chen EY
    Curr Opin Psychiatry; 2011 Nov; 24(6):455-60. PubMed ID: 21799414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.